WallStreetZenWallStreetZen

NASDAQ: ADMA
Adma Biologics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Adma Biologics revenue was $474.17M for the trailing 12 months ending Jun 30, 2025, with 486.7% growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was $122.0M, up 6.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ADMA annual revenue was $426.5M, with 65.2% growth year-over-year.

ADMA past revenue growth

How has ADMA's revenue growth performed historically?

Company
43.58%
Industry
149.5%
Market
17.71%
ADMA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ADMA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ADMA's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ADMA revenue history

Current Revenue
$474.2M
Current Earnings
$208.9M
Current Profit Margin
44.1%

Be the first to know when ADMA announces revenue.

ADMA Revenue History By Year

ADMA Yearly RevenueADMA RevenueADMA ChangeADMA Revenue Growth
2024-12-31$426.45M$168.24M+65.15%
2023-12-31$258.22M$104.14M+67.59%
2022-12-31$154.08M$73.14M+90.36%
2021-12-31$80.94M$38.72M+91.72%
2020-12-31$42.22M$12.87M+43.85%
2019-12-31$29.35M$12.36M+72.79%
2018-12-31$16.99M-$5.78M-25.37%
2017-12-31$22.76M$12.10M+113.49%
2016-12-31$10.66M$3.48M+48.53%
2015-12-31$7.18M$1.26M+21.34%
2014-12-31$5.92M$2.85M+92.84%
2013-12-31$3.07M$1.95M+174.35%
2012-12-31$1.12M$357.08k+46.92%
2011-12-31$761.04kN/AN/A

1 of 1

Adma Biologics Revenue FAQ

What was ADMA's revenue last quarter?

On Invalid Date, Adma Biologics (NASDAQ: ADMA) reported Q2 2025 revenue of $121.98 million up 13.8% year over year. In the same quarter last year, Adma Biologics's revenue was $107.19 million.

What was Adma Biologics's revenue in 2024?

Adma Biologics's annual revenue for the twelve months ending Dec 31, 2024 was $426.45 million, a 65.15% increase year over year.

How much does Adma Biologics make in a day?

Based on Adma Biologics annual revenue for the past five years, ADMA makes an average of $527,074.95 per day.

What was Adma Biologics's annual revenue growth in the past year?

As of Q3 2025, Adma Biologics's revenue has grown 43.58% year over year. This is 105.92 percentage points lower than the US Biotechnology industry revenue growth rate of 149.5%. Adma Biologics's revenue in the past year totaled $474.17 million.

How much does Adma Biologics make in a year?

Adma Biologics's revenue by year for the past five years is:
  • Adma Biologics's revenue for the twelve months ending Dec 31, 2024 was $426.45 million, a 65.15% increase year over year.
  • Adma Biologics's annual revenue for Dec 31, 2023 was $258.22 million, a 67.59% increase from 2022.
  • Adma Biologics's annual revenue for 2022 was $154.08 million, a 90.36% increase from 2021.
  • Adma Biologics's annual revenue for 2021 was $80.94 million, a 91.72% increase from 2020.
  • Adma Biologics's annual revenue for 2020 was $42.22 million, a 43.85% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.